Boehringer, Forma Strike Discovery Deal In Oncology
The German pharma pays $65 million upfront in a deal with high-ceilinged milestones, in an ambitious effort to discover cancer drugs that affect protein-protein interactions.
The German pharma pays $65 million upfront in a deal with high-ceilinged milestones, in an ambitious effort to discover cancer drugs that affect protein-protein interactions.